Cl-NQTrp signifcantly disrupts the preformed fbrillar aggregates of Tau-derived PHF6 (VQIVYK) peptide and full-length tau protein.
体外研究
Cl-NQTrp efciently disassembled pre-formed PHF6 peptide fbrils.
Cl-NQTrp has the potential to induce conformational changes in PHF6 peptide oligomers.
体内研究
Cl-NQTrp could be a unique potential therapeutic for AD since it targets aggregation of both Aβ and tau.
Cl-NQTrp significantly alleviates the shorter life span of htau-expressing flies, leading to 58% viability on day 29.
Animal Model:
Virgin females, carrying either the eye GMR -Gal4 driver or the pan-neuronal driver elav -Gal4 on chromosome X, were collected and crossed with males carrying UAS-h tau on the 2nd chromosome or with wild-type Oregon-R (OR) males as a control.
Dosage:
0.75 mg/mL.
Administration:
Dripped every other day.
Result:
Inhibited PHF6 aggregation and ameliorates eye neurodegeneration Drosophila overexpressing the human tau protein (htau).
分子式
C21H15N2O4Cl
分子量
394.81
CAS号
185351-23-9
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.